Applied BioCode Corporation designs, develops, and commercializes multiplex diagnostic testing products in California. Its products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the detection steps, PCR amplification, and hybridization and target capture; and the BioCode 2500 analyzer, a system that reads each barcode and quantifies the BMB target using the fluorescence signal intensity. The company develops assays, such as BioCode SARS-CoV-2 Assay, an assay for the detection of SARS-CoV-2 nucleic acid in nasopharyngeal swabs; and CoV-2 Flu Assay for detection of RNA and various Influenza, as well as offers gastrointestinal and respiratory pathogen panel related products. In addition, it provides BioCode Fungal Panel, a multiplexed deoxyribonucleic acid (DNA) amplification test; and BioCode STI + Resistance Panel (RUO), a multiplex nucleic acid amplification test. Further, the company offers barcoded magnetic bead accessories. Applied BioCode Corporation was founded in 2016 and is based in Grand Cayman, the Cayman Islands.
Frequently asked questions
What sector does Applied BioCode (6598) operate in?
Applied BioCode belongs to the Healthcare sector and operates in the Medical Devices industry.
What is Applied BioCode (6598) current stock price?
As of the latest data, Applied BioCode stock price is NT$27.75, with a previous close of NT$27.75.
What is Applied BioCode (6598) current market capitalization?
Applied BioCode market cap is approximately 2.85 billion.
What is Applied BioCode (6598) Earnings Per Share (EPS)?
The trailing EPS is -NT$1.41.
What is Applied BioCode (6598) EBITDA?
Applied BioCode EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 32.68 million.
Does Applied BioCode (6598) pay dividends?
No. Applied BioCode does not pay a dividend.
What is Applied BioCode (6598) beta (volatility) score?
Applied BioCode has a beta of 0.646, indicating lower volatility than the overall market.
